EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Flare phenomenon visualized by 99mTc-bone scintigraphy has prognostic value for patients with metastatic castration-resistant prostate cancer

Xue Zhang, Kenichi Nakajima, Atsushi Mizokami, Hiroyuki Horikoshi, Koshiro Nishimoto, Katsuyoshi Hashine, Hideyasu Matsuyama, Satoru Takahashi, Hiroshi Wakabayashi, Seigo Kinuya

Annals of Nuclear Medicine · 2024

DOI: 10.1007/s12149-024-01914-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Nuclear Medicine, 2024. Verfasst von Xue Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Kanazawa University, Kanazawa, Japan. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Bone Neoplasms, Radionuclide Imaging. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: PDRadiopharma, Kanazawa University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This study aimed to determine the prognostic value of the flare phenomenon in patients with metastatic castration-resistant prostate cancer (mCRPC) using the bone scan index (BSI) derived from 99m Tc-methylenediphosphonate (MDP) bone scintigraphy images.

Methods

We categorized 72 patients from the PROSTAT-BSI registry with mCRPC who were followed-up for 2 years after starting docetaxel chemotherapy to groups based on pre-chemotherapy BSI values of < 1, 1–4, and > 4. We assessed the effects of the flare phenomenon (defined as a > 10% increase in the BSI within 3 months of starting chemotherapy, followed by > 10% improvement within the next 3 months) on survival using Kaplan–Meier curves and Cox proportional hazard analyses.

Results

The flare phenomenon was found in 26 (36%) of the 72 patients. Prostate-specific antigen (PSA), alkaline phosphatase (ALP), and hemoglobin (Hb) levels steadily increased, then deteriorated in patients with and without flare, respectively. Elevated BSI and PSA values at 3 months after starting therapy and the absence of abiraterone or/and enzalutamide therapy led to poor 2-year overall survival (OS) in the group without flare. In contrast, no influence was noticeable in the group with flare. The results of multivariable analyses that included only factors associated with PSA and BSI showed that increased baseline BSI (hazard ratio [HR], 1.39; 95% confidence interval [CI], 1.04–1.86; P = 0.023) and PSA (HR, 7.15; 95% CI 2.13–24.04; P = 0.0015) values could be independent risk factors for patients with mCRPC without flare. However, these factors lost significance during flare. The risk for all-cause death was significantly higher among patients with BSI > 4 without, than with flare. The results of univariable analyses indicated that flare positively impacted survival (HR, 0.24; 95% CI 0.06‒0.91; P = 0.035). Multivariable analysis did not identify any factors that could predict outcomes.

Conclusion

Favorable prognosis, with fewer disturbances from other factors such as the use of abiraterone or/and enzalutamide, PSA changes, and BSI, was attainable in cases when the mCRPC patient demonstrated flare phenomenon. Follow-up bone scintigraphy at least every 3 months could help to determine the prognosis of patients with bone metastasis of mCRPC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantBone NeoplasmsRadionuclide ImagingHumansMaleAgedPrognosisMiddle AgedBone and BonesTechnetium Tc 99m MedronateAged, 80 and overProstate-Specific Antigen

Stichwörter der Autor:innen

BiomarkerBone scan indexChemotherapyMulticenter studyPrognosis

Substanzen

Technetium Tc 99m MedronateProstate-Specific Antigen

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Kanazawa University, Kanazawa, Japan.
  • Department of Functional Imaging and Artificial Intelligence, Kanazawa University, 13-1 Takara-machi, Kanazawa, 920-8640, Japan. nakajima@med.kanazawa-u.ac.jp.
  • Department of Urology, Kanazawa University, Kanazawa, Japan.
  • Department of Diagnostic Radiology, Gunma Prefectural Cancer Center, Ota, Japan.
  • Department of Uro-Oncology, Saitama Medical University International Medical Center, Saitama, Japan.
  • Department of Urology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.

Förderung

  • PDRadiopharma
  • Kanazawa University

Zitieren

APA

Zhang, X., Nakajima, K., Mizokami, A., Horikoshi, H., Nishimoto, K., Hashine, K., Matsuyama, H., Takahashi, S., Wakabayashi, H., & Kinuya, S. (2024). Flare phenomenon visualized by 99mTc-bone scintigraphy has prognostic value for patients with metastatic castration-resistant prostate cancer. Annals of Nuclear Medicine. https://doi.org/10.1007/s12149-024-01914-8

Vancouver

Zhang X, Nakajima K, Mizokami A, Horikoshi H, Nishimoto K, Hashine K, et al. Flare phenomenon visualized by 99mTc-bone scintigraphy has prognostic value for patients with metastatic castration-resistant prostate cancer. Annals of Nuclear Medicine. 2024. doi:10.1007/s12149-024-01914-8

BibTeX
@article{Zhang2024,
  author = {Zhang, Xue and Nakajima, Kenichi and Mizokami, Atsushi and Horikoshi, Hiroyuki and Nishimoto, Koshiro and Hashine, Katsuyoshi and Matsuyama, Hideyasu and Takahashi, Satoru and Wakabayashi, Hiroshi and Kinuya, Seigo},
  title = {Flare phenomenon visualized by 99mTc-bone scintigraphy has prognostic value for patients with metastatic castration-resistant prostate cancer},
  journal = {Annals of Nuclear Medicine},
  year = {2024},
  doi = {10.1007/s12149-024-01914-8}
}
Kostenlos starten →